ACHV
NASDAQ
US
Achieve Life Sciences, Inc. - Common Shares
$3.23
▲ +$0.09
(+2.87%)
Vol 504K
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$264.6M
ROE
-196.7%
Margin
-94.7%
D/E
29.39
Beta
1.88
52W
$2–$6
Wall Street Consensus
13 analysts · Apr 20262
Strong Buy
10
Buy
1
Hold
0
Sell
0
Strong Sell
92.3%
Buy Rating
Price Chart
Similar Stocks
TNXP
Tonix Pharmaceuticals Holding Corp
$199.7M
CRBP
Corbus Pharmaceuticals Holdings Inc
$142.9M
GALT
Galectin Therapeutics Inc
$268.2M
SGMT
Sagimet Biosciences Inc
$183.5M
CNTN
Canton Strategic Holdings Inc
CNTB
Connect Biopharma Holdings Ltd
$157.6M
PRLD
Prelude Therapeutics Inc
$164.2M
ARTV
Artiva Biotherapeutics Inc
$105.3M
RNAC
Cartesian Therapeutics Inc
$187.5M
Earnings
Beat rate: 40.0%
Next Report
May 11, 2026
EPS Estimate: $-0.32
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.32 | — | — |
| Dec 2025 | $-0.28 | $-0.28 | $0.00 |
| Sep 2025 | $-0.26 | $-0.28 | $-0.02 |
| Jun 2025 | $-0.37 | $-0.37 | +$0.00 |
Fundamentals Trend
| Metric | 2025-03-31 | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -176.1% | -193.5% | -193.5% | -193.5% | -196.7% | -196.7% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | -94.7% | -94.7% | -94.7% | -94.7% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 95.84 | 23.68 | 23.68 | 23.68 | 29.39 | 29.39 |
| Current Ratio | 3.51 | 6.64 | 6.64 | 6.64 | 5.14 | 5.14 |
Key Ratios
ROA (TTM)
-118.3%
P/S (TTM)
14.85
P/B
5.8
EPS (TTM)
$-1.38
Rev Growth 3Y
-44.7%
52W High
$5.78
52W Low
$1.84
$1.84
52-Week Range
$5.78
How does ACHV compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
ACHV valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
14.9
▲
16%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
5.8
▲
135%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
ACHV profitability vs Biotechnology peers
ROE
-196.7%
▼
192%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-94.7%
▲
67%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-118.3%
▼
153%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
ACHV financial health vs Biotechnology peers
D/E ratio
29.4
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
5.1
▲
16%
above
peers
(4.4)
vs Peers
vs Industry
Below avg
Beta
1.9
▲
94%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
ACHV fundamentals radar
ACHV
Peer median
Industry
ACHV profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
ACHV vs peers: key metrics
Latest News
No related news yet